124 related articles for article (PubMed ID: 38590270)
21. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
[TBL] [Abstract][Full Text] [Related]
22. Cardiac neuroendocrine tumour metastases: case reports and review of the literature.
Bonsen LR; Aalbersberg EA; Tesselaar M; Stokkel MP
Nucl Med Commun; 2016 May; 37(5):461-5. PubMed ID: 26671851
[TBL] [Abstract][Full Text] [Related]
23. Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT-correlation with Ga-68 DOTATATE PET/CT findings.
Gulpinar B; Peker E; Soydal C; Araz M; Elhan AH
Br J Radiol; 2020 Feb; 93(1106):20190735. PubMed ID: 31922897
[TBL] [Abstract][Full Text] [Related]
24. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
25. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
26. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
27. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
28. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
29.
Bélissant Benesty O; Nataf V; Ohnona J; Michaud L; Zhang-Yin J; Bertherat J; Chanson P; Reznik Y; Talbot JN; Montravers F
Endocrine; 2020 Mar; 67(3):708-717. PubMed ID: 31583575
[TBL] [Abstract][Full Text] [Related]
30. Early Dynamic 68Ga-DOTA-D-Phe1-Tyr3-Octreotide PET/CT in Patients With Hepatic Metastases of Neuroendocrine Tumors.
Sänger PW; Freesmeyer M
Clin Nucl Med; 2016 Jun; 41(6):447-53. PubMed ID: 26859210
[TBL] [Abstract][Full Text] [Related]
31. Potential for Increasing Uptake of Radiolabeled
Pollard JH; Menda Y; Zamba KD; Madsen M; O'Dorisio MS; O'Dorisio T; Bushnell D
Cancer Biother Radiopharm; 2021 Oct; 36(8):632-641. PubMed ID: 34252288
[No Abstract] [Full Text] [Related]
32. First
Bertani E; Collamati F; Colandrea M; Faccini R; Fazio N; Ferrari ME; Fischetti M; Fumagalli Romario U; Funicelli L; De Simoni M; Mancini-Terracciano C; Mirabelli R; Morganti S; Papi S; Pisa E; Solfaroli-Camillocci E; Spada F; Cremonesi M; Grana CM
Cancer Biother Radiopharm; 2021 Jun; 36(5):397-406. PubMed ID: 33601932
[No Abstract] [Full Text] [Related]
33. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
34. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on
Gauthé M; Testart Dardel N; Ruiz Santiago F; Ohnona J; Nataf V; Montravers F; Talbot JN
Eur Radiol; 2018 Sep; 28(9):3943-3952. PubMed ID: 29532242
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours.
Schreiter NF; Nogami M; Steffen I; Pape UF; Hamm B; Brenner W; Röttgen R
Eur Radiol; 2012 Feb; 22(2):458-67. PubMed ID: 21904802
[TBL] [Abstract][Full Text] [Related]
36. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H
Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582
[TBL] [Abstract][Full Text] [Related]
37. A case of positive
Zilli A; Fanetti I; Conte D; Massironi S
Clin Imaging; 2018; 49():156-158. PubMed ID: 29529451
[TBL] [Abstract][Full Text] [Related]
38. Localization of Unknown Primary Site with
Menda Y; O'Dorisio TM; Howe JR; Schultz M; Dillon JS; Dick D; Watkins GL; Ginader T; Bushnell DL; Sunderland JJ; Zamba GKD; Graham M; O'Dorisio MS
J Nucl Med; 2017 Jul; 58(7):1054-1057. PubMed ID: 28153957
[TBL] [Abstract][Full Text] [Related]
39. Clinical and Prognostic Value of PET/CT Imaging with Combination of
Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
[TBL] [Abstract][Full Text] [Related]
40. Value of
Imperiale A; Boursier C; Sahakian N; Ouvrard E; Chevalier E; Sebag F; Addeo P; Taïeb D
J Nucl Med; 2022 Mar; 63(3):384-388. PubMed ID: 34272321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]